サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1643909

静脈ステントの世界市場（2025年～2033年）

Global Venous Stents Market - 2025-2033

出版日
ページ情報
英文 176 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=147.28円
静脈ステントの世界市場（2025年～2033年）
出版日: 2025年01月27日
発行: DataM Intelligence
ページ情報: 英文 176 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

世界の静脈ステントの市場規模は、2024年に12億4,000万米ドルに達し、2033年には26億2,000万米ドルに達すると予測され、予測期間2025年～2033年にはCAGR8.5％で成長する見込みです。

静脈ステントは、拡張可能な金属メッシュチューブであり、閉塞または狭窄した静脈の壁に圧力を加え、静脈の開通を維持する足場として機能します。通常、腹部、胸部、下肢にある太い中心静脈に留置されます。静脈ステントは、慢性の深部静脈血栓症（DVT）、血液透析・動静脈瘻、May-Thurner症候群、ナットクラッカー症候群、血栓後症候群の治療に使用されます。DVTは、脚から心臓や肺に血液を戻す太い深部静脈のいずれかに血栓ができる状態と定義されます。

市場力学：

促進要因と抑制要因

技術進歩の台頭

技術の進歩は、ステント留置術の有効性、安全性、寿命を向上させることにより、世界の静脈ステント市場の成長を促進しています。ニチノールのような生体適合性合金は柔軟性と耐久性を高め、合併症を減少させます。薬剤溶出ステントは再狭窄を防ぐために薬剤を放出し、再手術の必要性を減らします。自己拡張型ステントやバルーン拡張型ステントは、低侵襲手術の際に使いやすく、回復時間の短縮と患者の体感の向上を可能にします。

さらに、ステント設計の技術的進歩は避けられないものであり、データ収集を上回る可能性が高いです。現在のステントは主にレーザーカットのニチノール製で、オープン型やハイブリッド型もあります。将来の設計では、薬剤コーティングや、ポアソン効果やフローなどの因子に影響を与える代替設計が組み込まれるかもしれません。開存率低下の要因とステント血栓および閉塞の生物学的機序を理解することはステント失敗予防にとって極めて重要です。

合併症と再狭窄のリスク

世界の静脈ステント市場は、合併症や再狭窄のリスクによる厄介な問題に直面しており、静脈ステント留置術の長期的な有効性と安全性に関する疑問が投げかけられています。ステントの技術的進歩があったとしても、ステント血栓症、感染症、静脈の再狭窄などの障害は依然として存在し、さらなる処置や回復期間の延長、外科的介入につながる可能性があります。このような恐怖は、時には患者や医療提供者にまで向けられ、静脈ステントを選択肢として考慮しないということもあります。そのため、採用率はかなり低く、市場全体の可能性は限られています。これが医療業界における静脈ステントの出現と受け入れの妨げとなっています。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 技術進歩の高まり
    • 抑制要因
      • 合併症および再狭窄のリスク
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析

第6章 製品タイプ別

  • カバー付きステント
  • 自己拡張型ステント
  • バルーン拡張型ステント
  • ベアステント

第7章 材料別

  • ニチノール
  • 金属ステント
  • ステンレス鋼
  • ポリマー
  • その他

第8章 用途別

  • 深部静脈血栓症（DVT）
  • 慢性静脈不全（CVI）
  • 肺塞栓症（PE）
  • 腫瘍閉塞
  • その他

第9章 エンドユーザー別

  • 病院
  • 専門クリニック
  • 外来手術センター

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • スペイン
    • イタリア
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • 韓国
    • その他アジア太平洋
  • 中東・アフリカ

第11章 競合情勢

  • 競合シナリオ
  • 市況・シェア分析
  • M&A分析

第12章 企業プロファイル

  • Medtronic Plc
    • 会社概要
    • 製品ポートフォリオ
      • 製品説明
      • 製品の主要業績評価指標（KPI）
      • 実績および予測の製品販売
      • 製品販売量
    • 財務概要
      • 企業収益
      • 地域別収益シェア
      • 収益予測
    • 主な発展
      • 合併と買収
      • 主な製品開発活動
      • 規制当局の承認等
    • SWOT分析
  • Boston Scientific Corporation
  • Cook Medical
  • Terumo Corporation
  • Becton, Dickinson and Company（BD）
  • Abbott Laboratories
  • Cordis Corporation（Cardinal Health）
  • Vesper Medical
  • Bentley
  • Optimed Medizinische Instrumente GmbH
  • Endologix
    • パイプライン製品の説明
    • 製品の主要業績評価指標（KPI）
    • 主な活動
    • 市場参入のタイムライン
    • 製品普及率
    • 売上推定と予測
  • Medi-Globe
  • Aortic Ltd
  • Intra-Op
  • Jotec GmbH

第12章 付録

目次
Product Code: MD8057

The global venous stents market reached US$ 1.24 billion in 2024 and is expected to reach US$ 2.62 billion by 2033, growing at a CAGR of 8.5% during the forecast period 2025-2033.

Venous stents are expandable metal mesh tubes which apply pressure to walls of blocked or narrowed veins and act as a scaffold to keep the veins open. They are usually placed in the bigger central veins located in the abdomen, chest, and legs. Venous stents are used to treat chronic deep vein thrombosis (DVT), hemodialysis/arteriovenous fistulae, May-Thurner syndrome, Nutcracker syndrome, and post-thrombotic syndrome. DVT is defined as the condition where a blood clot develops in one of the large, deep veins, which brings back blood from the leg to the heart and lungs.

Market Dynamics: Drivers & Restraints

Rise in the Technological Advancements

Technological advancements are driving the global venous stents market growth by improving the effectiveness, safety, and longevity of stenting procedures. Biocompatible alloys like nitinol enhance flexibility and durability, reducing complications. Drug-eluting stents release medication to prevent restenosis, reducing the need for repeat procedures. Self-expanding and balloon-expandable stents provide ease of use during minimally invasive surgeries, allowing quicker recovery times and better patient experiences.

Moreover, technological advancements in stent design are inevitable and likely to outpace data collection. Current stents are mainly laser-cut nitinol designs, with some open and hybrid designs. Future designs may incorporate drug coating and alternative designs to influence factors like the Poisson effect or flow. Understanding factors driving patency loss and the biological mechanism of stent thrombosis and occlusion is crucial for stent failure prevention.

Risk of Complications and Restenosis

The global venous stents market is facing some complications due to the risk of complications and restenosis, which instigate questions regarding the long-term effectiveness and safety of venous stenting procedures. Even though there has been technological advancement in stents, barriers such as stent thrombosis, infection, or re-narrowing of the vein still exist and might lead to further procedures, prolonged recovery, or some surgical intervention. This fear sometimes turns out towards the patient or even the healthcare provider and sometimes does not consider venous stents as an option. Hence, it has a rather slow adoption rate and limits overall market potential. This stems the emergence and acceptance of venous stests in the healthcare industry.

For more details on this report - Request for Sample

Segment Analysis

The global venous stents market is segmented based on product type, material, application end user and region.

Product Type:

Covered Stents from the device segment is expected to dominate the Venous Stents market share

The covered stents segment holds a major portion of the venous stents market share and is expected to continue to hold a significant portion of the venous stents market share during the forecast period.

Covered stents are a vital segment in the global market for venous stents, by offering further protection from restenosis and other complications. Covered stents differ from bare metal stents in that their luminal surfaces are lined with a synthetic material to physically restrict tissue ingrowth, thereby reducing the risk of thrombosis, preventing re-narrowing of a vein. Thus they can be ideal for use in complicated situations, such as stenosis of large veins, or those susceptible to occlusion. In fact, covered stents are often preferred in high-risk patients due to the better long-term patency and likelihood of re-treatment.

For instance, in October 2023, Getinge has launched its iCast covered stent system for treating iliac arterial occlusive disease in the US, having received FDA premarket approval in March 2023. The balloon expandable polytetrafluoroethylene-covered stent is marketed outside the US as Advanta V12, according to Getinge.

End User:-

Hospitals segment is the fastest-growing segment in Venous Stents market share

The oncology segment is the fastest-growing segment in the venous stents market share and is expected to hold the market share over the forecast period.

Hospitals are the major healthcare providers in the global venous stents market by offering interventional radiology, vascular surgery, and cardiology in specialty services. Hospitals provide infrastructure and medical expertise for safe stent implantation by proper patient selection and post-procedural care. The increasing number of patients diagnosed with venous conditions has become a demand driver for venous stenting procedures, such as chronic venous insufficiency and deep vein thrombosis. Hospitals also train patients and physicians on the advantages and disadvantages of stenting. With the adoption of advanced stenting technologies, it can contribute to the market growth and acceptance of such forms of treatment.

Geographical Analysis

North America is expected to hold a significant position in the Venous Stents market share

North America holds a substantial position in the venous stents market and is expected to hold most of the market share due to advanced healthcare infrastructure accompanied by increasing prevalence of venous diseases such as DVT and CVI. Moreover, product launches, ongoing studies, demand for advanced treatment solutions is complemented by the geriatric population and alarming obesity statistics helps in the region growth. The sophisticated reimbursement mechanisms and the forceful active market players are conducive to a stimulating atmosphere for the development of innovative stent technologies while increased awareness channels between minimally invasive treatment options.

For instance, in March 2023, W. L. Gore & Associates has enrolled the first U.S. patient in a prospective, non-randomized, multicenter, single-arm study to evaluate the GORE VIAFORT Vascular Stent for treating symptomatic inferior Vena Cava obstruction with or without combined Iliofemoral Obstruction.

Hence, W. L. Gore & Associates is ongoing clinical trials on the GORE VIAFORT Vascular Stent, aiming to improve treatment options for venous obstructions and stimulate market growth by validating new therapeutic approaches and improving patient care outcomes.

Europe is growing at the fastest pace in the Venous Stents market

Europe holds the fastest pace in the venous stents market and is expected to hold most of the market share due to launches of significant products, healthcare expenditures, and development in the medical technology field. Hence, these factors drive the venous market for stents in Europe. Other factors that will drive the market include an aging population, government programs for chronic diseases, and the progress of clinical trials. A highly systematized and organized health structure provides timely diagnosis and treatment, thus increasing the venous stent uptake in Europe.

For instance, in June 2024 Philips has successfully implanted the Duo Venous Stent System, an implantable medical device designed to treat symptomatic venous outflow obstruction in patients with chronic venous insufficiency, following premarket approval from the U.S. FDA.

Competitive Landscape

The major global players in the venous stents market include Medtronic Plc, Boston Scientific Corporation, Cook Medical, Terumo Corporation, Becton, Dickinson and Company (BD), Abbott Laboratories, Cordis Corporation(Cardinal Health), Vesper Medical, Bentley, Optimed Medizinische Instrumente GmbH and among others.

Key Developments

  • In April 2024, Getinge has received EU MDR certification for its Advanta V12 covered stent system, which is used for patients with aortoiliac occlusive disease, including aortic bifurcation lesions. This certification confirms the system's compliance with EU regulations and reflects Getinge's commitment to quality and patient safety.
  • In July 2023, Steven Abramowitz, MD, at MedStar Washington Hospital Center, completed the first deep venous stent thrombosis procedures using a minimally invasive thrombectomy catheter, RevCore, which received FDA clearance in March and was officially launched in June. The stent cleaner is a deep venous "stent cleaner."

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global venous stents market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Material Type & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Product Type
  • 3.2. Snippet by Material
  • 3.3. Snippet by Applications
  • 3.4. Snippet by Distribution Channel
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rise in the Technological Advancements
    • 4.1.2. Restraints
      • 4.1.2.1. Risk of Complications and Restenosis
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. By Product Type

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 6.1.2. Market Attractiveness Index, By Product Type
  • 6.2. Covered Stents*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Self-Expanding Stents
  • 6.4. Balloon-Expandable Stents
  • 6.5. Bare Stents

7. By Material

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material
    • 7.1.2. Market Attractiveness Index, By Material
  • 7.2. Nitinol*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Metal Stents
  • 7.4. Stainless Steel
  • 7.5. Polymers
  • 7.6. Others

8. By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. Deep Vein Thrombosis (DVT)*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Chronic Venous Insufficiency (CVI)
  • 8.4. Pulmonary Embolism (PE)
  • 8.5. Tumor Occlusion
  • 8.6. Others

9. By End-User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 9.1.2. Market Attractiveness Index, By End User
  • 9.2. Hospitals*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Specialty Clinics
  • 9.4. Ambulatory Surgical Centers

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.7.1. U.S.
      • 10.2.7.2. Canada
      • 10.2.7.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.7.1. Germany
      • 10.3.7.2. U.K.
      • 10.3.7.3. France
      • 10.3.7.4. Spain
      • 10.3.7.5. Italy
      • 10.3.7.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.7.1. Brazil
      • 10.4.7.2. Argentina
      • 10.4.7.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.7.1. China
      • 10.5.7.2. India
      • 10.5.7.3. Japan
      • 10.5.7.4. South Korea
      • 10.5.7.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

Key Market Players

  • 12.1. Medtronic Plc*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio
      • 12.1.2.1. Product Description
      • 12.1.2.2. Product Key Performance Indicators (KPIs)
      • 12.1.2.3. Historic and Forecasted Product Sales
      • 12.1.2.4. Product Sales Volume
    • 12.1.3. Financial Overview
      • 12.1.3.1. Company Revenue's
      • 12.1.3.2. Geographical Revenue Shares
      • 12.1.3.3. Revenue Forecasts
    • 12.1.4. Key Developments
      • 12.1.4.1. Mergers & Acquisitions
      • 12.1.4.2. Key Product Development Activities
      • 12.1.4.3. Regulatory Approvals etc.
    • 12.1.5. SWOT Analysis
  • 12.2. Boston Scientific Corporation
  • 12.3. Cook Medical
  • 12.4. Terumo Corporation
  • 12.5. Becton, Dickinson and Company (BD)
  • 12.6. Abbott Laboratories
  • 12.7. Cordis Corporation(Cardinal Health)
  • 12.8. Vesper Medical
  • 12.9. Bentley
  • 12.10. Optimed Medizinische Instrumente GmbH
  • Similar data will be provided for each market player.

Emerging Market Players

  • 12.11. Endologix*
    • 12.11.1. Pipeline Products Description
    • 12.11.2. Product Key Performance Indicators (KPIs)
    • 12.11.3. Key Activities
    • 12.11.4. Market Entry Timelines
    • 12.11.5. Product Penetration Rate
    • 12.11.6. Sales Estimation and Projections
  • 12.12. Medi-Globe
  • 12.13. Aortic Ltd
  • 12.14. Intra-Op
  • 12.15. Jotec GmbH
  • Similar data will be provided for each market player.

LIST NOT EXHAUSTIVE

12. Appendix

  • 12.1 About Us and Services
  • 12.2 Contact Us